Table 4.
Tumour characteristics: RP cohort (n = 63).
| T stage | N (%) | Gleason score at margin | N (%) |
|---|---|---|---|
| T1-2a | 20 (32%) | 3 | 7 (11%) |
| T2b | 1 (1%) | 4 | 17 (27%) |
| T2c-4 | 37 (59%) | 5 | 2 (3%) |
| Unknown | 5 (8%) | Unknown | 37 (59%) |
|
| |||
| Nodal status | N (%) | Seminal vesicle involvement | N (%) |
|
| |||
| Negative | 44 (70%) | No | 41 (65%) |
| Positive | 9 (14%) | Unilateral | 11 (17%) |
| Unknown | 10 (16%) | Bilateral | 5 (8%) |
| Unknown | 6 (10%) | ||
|
| |||
| Gleason score | N (%) | Vascular space involvement | N (%) |
|
| |||
| 7 | 29 (46%) | No | 40 (63%) |
| 8 | 11 (17%) | Yes | 15 (24%) |
| 9 | 20 (32%) | Unknown | 8 (13%) |
| Unknown | 3 (5%) | ||
|
| |||
| D'Amico Risk Group | N (%) | Perineural involvement | N (%) |
|
| |||
| Intermediate | 31 (49%) | No | 36 (57%) |
| High | 29 (46%) | Yes | 17 (27%) |
| Unknown | 3 (5%) | Unknown | 10 (16%) |
|
| |||
| Extracapsular extension | N (%) | Lymph node dissection (LND) | N (%) |
|
| |||
| Absent | 19 (30%) | No | 25 (40%) |
| Present | 41 (65%) | Yes | 37 (59%) |
| Unknown | 3 (5%) | N/A or unknown | 1 (1%) |
|
| |||
| Positive margin | N (%) | Extended LND | N (%) |
|
| |||
| Absent | 34 (54%) | No | 20 (32%) |
| Present | 27 (43%) | Yes | 22 (35%) |
| Unknown | 2 (3%) | Unknown | 21 (33%) |